Related Experiment Videos

Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients

Claudia Cappuzzello1, Monica Napolitano, Diego Arcelli

  • 1Laboratorio di Patologia Vascolare, Istituto Dermopatico dell'Immacolata IRCCS, Rome.

Physiological Genomics
|April 2, 2009
PubMed

Insights

Researchers identified key gene expression patterns in peripheral blood mononuclear cells (PBMCs) to find biomarkers for chronic heart failure (CHF). Chemokine receptor and early growth response genes were upregulated in CHF patients, with EGR1 distinguishing between ischemic and non-ischemic types.

Area of Science:

  • Cardiovascular Biology
  • Molecular Genetics
  • Biomarker Discovery

Background:

  • Chronic heart failure (CHF) poses a significant health burden, necessitating novel diagnostic and prognostic tools.
  • Peripheral blood mononuclear cells (PBMCs) offer a readily accessible source for identifying molecular signatures of disease.
  • Distinguishing between ischemic (ICM) and non-ischemic dilated (NIDCM) cardiomyopathy is crucial for targeted treatment.

Purpose of the Study:

  • To identify gene expression biomarkers for chronic heart failure (CHF) in PBMCs.
  • To differentiate molecular signatures between ICM and NIDCM patient groups.
  • To validate potential CHF biomarkers using quantitative methods.

Main Methods:

  • PBMC gene expression profiling using Affymetrix microarrays in CHF patients (ICM and NIDCM) and controls.
  • Bioinformatic analyses including Gene Ontology (GO), Prediction Analysis of Microarrays (PAM), and Significance Analysis of Microarrays (SAM).
  • Validation of candidate biomarkers via quantitative real-time polymerase chain reaction (qRT-PCR).

Main Results:

  • A distinct gene expression profile was identified, differentiating CHF patients from healthy controls.
  • Upregulation of chemokine receptor (CCR2, CX(3)CR1) and early growth response (EGR1, 2, 3) gene families in CHF patients.
  • Early Growth Response 1 (EGR1) expression levels demonstrated the ability to discriminate between ICM and NIDCM.

Conclusions:

  • This study presents the first large-scale gene expression analysis of CHF PBMCs, revealing a molecular signature.
  • Chemokine receptor and EGR family members are identified as putative biomarkers for chronic heart failure.
  • EGR1 serves as a potential biomarker for differentiating between ischemic and non-ischemic dilated cardiomyopathy.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...